oasis 1 oral semaglutide 50 mg nejm 2023 obesity at a Dose of 25 in Adults with Overweight or Oral semaglutide 50 mg taken

S.Dal-PontG

McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J (2016) Health-related quality of life measured using the EQ-5D-5L: South Australian population norms

Microdosing GLP-1 medications lacks clinical evidence, meaning doctors dont have enough reliable data to confirm whether lower than approved doses are effective

If the drugs are directly both improving weight reduction and cancer reduction, then we need to double down. Ganta wonders the same thing about the drugs apparent positive effects on several conditions, from dementia to sleep apnea: Is it that obesity is causing or contributing to the problem [and that weight loss is causing the improvement], or is the medication directly having an impact through a different mechanism? She hopes there will be more research to parse this out in the years to come